teddit

overwhelming feedback from new users is that the content on farcaster is often too farcaster-centric.

sharing a few topics i would love to read more on farcaster (and please lmk if any of these are in your wheelhouse bc i would love to help amplify!):

1. popular culture! trend analyses and insights on culture (and not crypto culture). tell us what do gen z and gen alpha (and sure, millennial) consumers care about. i know "men in tech" may not care about this, but plenty of women *do* and there's a lot of us here!

2. start ups! tell us which startups are hitting milestones, getting funding, growing exponentially — and tell us whether you think they are worthwhile businesses or not.

3. data-centric information about technology, the economy, psychology, and everyday life. i love seeing data visualizations behind things that we know and love.

4. more SCIENCE! tell us how pigs could solve the organ donor crisis or why sunshine is good for the immune system. anything!

what do you want to read more of here?

So, #4

My startup is legitimately planning to use Sinclair Minipigs (or another large-format animal) for our curative stage IV breast cancer (bone mets) therapy.

One of the difficult things about this is that there isn't an easy way to give pigs breast cancer (you have to completely immunosuppress them and inject them with human breast cancer). 

Sooooo we might be focusing on another cancer like prostate, lung, or osteosarcoma to start, instead. Still trying to work this out...

Meridian Radiopharmaceuticals
https://www.meridianradiopharmaceuticals.com/

How is this curative?  Wouldn't mets be an issue especially in stage 4 disease?

Scientist, crypto enthusiast, dog lover, amateur photographer, Cat Town Farcaster Community Leader

Immunotherapy is super dope - met a dude who got something similar to yescarta for MM and has been cancer free for four years.

Ah cool, makes sense.  We're going more with the immunotherapy route making masked T-Cell Engagers, could be a game changer for most solid tumors.  Currently in clinical trials, going well so far but still in phase one

This is meant to specifically address bone mets.